Xilio Therapeutics, Inc. financial data

Symbol
XLO on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 217% % 4.4%
Debt-to-equity 1522% % 832%
Return On Equity -858% % -299%
Return On Assets -53% % 35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52,500,328 shares 19%
Common Stock, Shares, Outstanding 51,829,013 shares 18%
Entity Public Float $41,500,000 USD -39%
Common Stock, Value, Issued $5,000 USD 25%
Weighted Average Number of Shares Outstanding, Basic 144,106,869 shares 127%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $19,066,000 USD 743%
Research and Development Expense $46,753,000 USD 6%
General and Administrative Expense $28,826,000 USD 17%
Operating Income (Loss) $43,775,000 USD 33%
Nonoperating Income (Expense) $14,714,000 USD -745%
Net Income (Loss) Attributable to Parent $58,489,000 USD 6.9%
Earnings Per Share, Basic 0 USD/shares 73%
Earnings Per Share, Diluted 0 USD/shares 73%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $103,764,000 USD 69%
Assets, Current $124,089,000 USD 96%
Property, Plant and Equipment, Net $3,679,000 USD -24%
Operating Lease, Right-of-Use Asset $4,125,000 USD -13%
Other Assets, Noncurrent $92,000 USD -53%
Assets $133,694,000 USD 79%
Accounts Payable, Current $2,300,000 USD 137%
Accrued Liabilities, Current $8,952,000 USD -8.6%
Liabilities, Current $56,401,000 USD 48%
Operating Lease, Liability, Noncurrent $5,960,000 USD -18%
Liabilities $141,789,000 USD 164%
Retained Earnings (Accumulated Deficit) $429,149,000 USD -16%
Stockholders' Equity Attributable to Parent $8,095,000 USD -139%
Liabilities and Equity $133,694,000 USD 79%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $28,978,000 USD
Net Cash Provided by (Used in) Financing Activities $4,832,000 USD 406%
Net Cash Provided by (Used in) Investing Activities $22,000 USD
Common Stock, Shares Authorized 600,000,000 shares 200%
Common Stock, Shares, Issued 51,829,013 shares 18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $33,788,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $105,565,000 USD 67%
Interest Paid, Excluding Capitalized Interest, Operating Activities $62,000 USD -70%
Deferred Tax Assets, Valuation Allowance $112,522,000 USD 21%
Deferred Tax Assets, Gross $114,979,000 USD 20%
Operating Lease, Liability $8,142,000 USD -11%
Depreciation $300,000 USD -25%
Payments to Acquire Property, Plant, and Equipment $22,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $58,489,000 USD 6.9%
Lessee, Operating Lease, Liability, to be Paid $9,985,000 USD -15%
Property, Plant and Equipment, Gross $12,139,000 USD 2%
Operating Lease, Liability, Current $1,303,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,839,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,785,000 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,843,000 USD -27%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,894,000 USD 3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,951,000 USD 3%
Additional Paid in Capital $421,049,000 USD 7.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $497,000 USD 12%
Deferred Tax Assets, Net of Valuation Allowance $2,457,000 USD -17%
Share-based Payment Arrangement, Expense $5,525,000 USD -19%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%